| | | | |
CUSIP No. 19240Q201 | | Schedule 13G | | Page 7 of 14 |
ITEM 1. (a) | Name of Issuer: |
Cogent Biosciences, Inc. (the “Issuer”)
| (b) | Address of Issuer’s Principal Executive Offices: |
200 Cambridge Park Drive, Suite 2500, Cambridge, Massachusetts 02140.
ITEM 2. (a) | Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
Ally Bridge MedAlpha Master Fund L.P. (“MedAlpha”)
Ally Bridge MedAlpha Management L.P.
Ally Bridge MedAlpha Management GP, LLC
Ally Bridge Group (NY) LLC
ABG Management Ltd.
Fan Yu
| (b) | Address or Principal Business Office: |
The address of the Reporting Persons is c/o Ally Bridge Group (NY) LLC, 430 Park Avenue, 12th Floor, New York, NY 10022.
| (c) | Citizenship of each Reporting Person is: |
Ally Bridge MedAlpha Master Fund L.P., Ally Bridge MedAlpha Management L.P., Ally Bridge MedAlpha Management GP, LLC and ABG Management Ltd. are entities organized under the laws of the Cayman Islands.
Ally Bridge Group (NY) LLC is an entity organized under the laws of the State of Delaware.
Mr. Fan Yu is a citizen of Hong Kong.
| (d) | Title of Class of Securities: |
Common Stock, par value $0.001 per share (“Common Stock”).
19240Q201